Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies development
This work aims to review the role of endothelial dysfunction underlying the main complications appearing early after autologous and allogeneic hematopoietic cell transplantation (HCT). The endothelial damage as the pathophysiological substrate of sinusoidal obstruction syndrome (SOS) is well establi...
| Main Authors: | , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-11-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1050994/full |
| _version_ | 1811219240188903424 |
|---|---|
| author | Ana Belén Moreno-Castaño Ana Belén Moreno-Castaño Ana Belén Moreno-Castaño María Queralt Salas Marta Palomo Marta Palomo Marta Palomo Julia Martinez-Sanchez Julia Martinez-Sanchez Montserrat Rovira Francesc Fernández-Avilés Carmen Martínez Joan Cid Joan Cid Pedro Castro Pedro Castro Pedro Castro Gines Escolar Gines Escolar Gines Escolar Enric Carreras Enric Carreras Maribel Diaz-Ricart Maribel Diaz-Ricart Maribel Diaz-Ricart |
| author_facet | Ana Belén Moreno-Castaño Ana Belén Moreno-Castaño Ana Belén Moreno-Castaño María Queralt Salas Marta Palomo Marta Palomo Marta Palomo Julia Martinez-Sanchez Julia Martinez-Sanchez Montserrat Rovira Francesc Fernández-Avilés Carmen Martínez Joan Cid Joan Cid Pedro Castro Pedro Castro Pedro Castro Gines Escolar Gines Escolar Gines Escolar Enric Carreras Enric Carreras Maribel Diaz-Ricart Maribel Diaz-Ricart Maribel Diaz-Ricart |
| author_sort | Ana Belén Moreno-Castaño |
| collection | DOAJ |
| description | This work aims to review the role of endothelial dysfunction underlying the main complications appearing early after autologous and allogeneic hematopoietic cell transplantation (HCT). The endothelial damage as the pathophysiological substrate of sinusoidal obstruction syndrome (SOS) is well established. However, there is growing evidence of the involvement of endothelial dysfunction in other complications, such as acute graft-versus-host disease (aGVHD) and transplant-associated thrombotic microangiopathy (TA-TMAs). Moreover, HCT-related endotheliopathy is not only limited to the HCT setting, as there is increasing evidence of its implication in complications derived from other cellular therapies. We also review the incidence and the risk factors of the main HCT complications and the biological evidence of the endothelial involvement and other linked pathways in their development. In addition, we cover the state of the art regarding the potential use of the biomarkers of endotheliopathy in the prediction, the early diagnosis, and the follow-up of the HCT complications and summarize current knowledge points to the endothelium and the other linked pathways described as potential targets for the prevention and treatment of HCT-complications. Lastly, the endothelium-focused therapeutic strategies that are emerging and might have a potential impact on the survival and quality of life of post-HCT-patients are additionally reviewed. |
| first_indexed | 2024-04-12T07:22:49Z |
| format | Article |
| id | doaj.art-7d37b10357bc41959f0acb7f8475a58c |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-12T07:22:49Z |
| publishDate | 2022-11-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-7d37b10357bc41959f0acb7f8475a58c2022-12-22T03:42:16ZengFrontiers Media S.A.Frontiers in Immunology1664-32242022-11-011310.3389/fimmu.2022.10509941050994Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies developmentAna Belén Moreno-Castaño0Ana Belén Moreno-Castaño1Ana Belén Moreno-Castaño2María Queralt Salas3Marta Palomo4Marta Palomo5Marta Palomo6Julia Martinez-Sanchez7Julia Martinez-Sanchez8Montserrat Rovira9Francesc Fernández-Avilés10Carmen Martínez11Joan Cid12Joan Cid13Pedro Castro14Pedro Castro15Pedro Castro16Gines Escolar17Gines Escolar18Gines Escolar19Enric Carreras20Enric Carreras21Maribel Diaz-Ricart22Maribel Diaz-Ricart23Maribel Diaz-Ricart24Hemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic, Barcelona, SpainClínic, Institut Josep Carreras, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, SpainHematology Department, Bone Marrow Transplantation Unit, Institut Clínic de Malalties Hemato-Oncològiques (ICMHO), Hospital Clínic, Barcelona, SpainHemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic, Barcelona, SpainClínic, Institut Josep Carreras, Barcelona, SpainCampus Clinic, Hospital Clinic de Barcelona, Barcelona, SpainClínic, Institut Josep Carreras, Barcelona, SpainCampus Clinic, Hospital Clinic de Barcelona, Barcelona, SpainHematology Department, Bone Marrow Transplantation Unit, Institut Clínic de Malalties Hemato-Oncològiques (ICMHO), Hospital Clínic, Barcelona, SpainHematology Department, Bone Marrow Transplantation Unit, Institut Clínic de Malalties Hemato-Oncològiques (ICMHO), Hospital Clínic, Barcelona, SpainHematology Department, Bone Marrow Transplantation Unit, Institut Clínic de Malalties Hemato-Oncològiques (ICMHO), Hospital Clínic, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, SpainApheresis & Cellular Therapy Unit, Department of Hemotherapy and Hemostasis, Institut Clínic de Malalties Hemato-Oncològiques (ICMHO), Hospital Clínic de Barcelona, Barcelona, SpainClínic, Institut Josep Carreras, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, SpainMedical Intensive Care Unit, Hospital Clínic de Barcelona, Universitat de Barcelona, Barcelona, SpainHemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic, Barcelona, SpainClínic, Institut Josep Carreras, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, SpainClínic, Institut Josep Carreras, Barcelona, SpainCampus Clinic, Hospital Clinic de Barcelona, Barcelona, SpainHemostasis and Erythropathology Laboratory, Hematopathology, Pathology Department, Centre de Diagnòstic Biomèdic (CDB), Hospital Clínic, Barcelona, SpainClínic, Institut Josep Carreras, Barcelona, SpainInstitut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, SpainThis work aims to review the role of endothelial dysfunction underlying the main complications appearing early after autologous and allogeneic hematopoietic cell transplantation (HCT). The endothelial damage as the pathophysiological substrate of sinusoidal obstruction syndrome (SOS) is well established. However, there is growing evidence of the involvement of endothelial dysfunction in other complications, such as acute graft-versus-host disease (aGVHD) and transplant-associated thrombotic microangiopathy (TA-TMAs). Moreover, HCT-related endotheliopathy is not only limited to the HCT setting, as there is increasing evidence of its implication in complications derived from other cellular therapies. We also review the incidence and the risk factors of the main HCT complications and the biological evidence of the endothelial involvement and other linked pathways in their development. In addition, we cover the state of the art regarding the potential use of the biomarkers of endotheliopathy in the prediction, the early diagnosis, and the follow-up of the HCT complications and summarize current knowledge points to the endothelium and the other linked pathways described as potential targets for the prevention and treatment of HCT-complications. Lastly, the endothelium-focused therapeutic strategies that are emerging and might have a potential impact on the survival and quality of life of post-HCT-patients are additionally reviewed.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1050994/fullendothelialbiomarkersearly HCT complicationslaboratory diagnosisprognosis assessmentresponse assessment |
| spellingShingle | Ana Belén Moreno-Castaño Ana Belén Moreno-Castaño Ana Belén Moreno-Castaño María Queralt Salas Marta Palomo Marta Palomo Marta Palomo Julia Martinez-Sanchez Julia Martinez-Sanchez Montserrat Rovira Francesc Fernández-Avilés Carmen Martínez Joan Cid Joan Cid Pedro Castro Pedro Castro Pedro Castro Gines Escolar Gines Escolar Gines Escolar Enric Carreras Enric Carreras Maribel Diaz-Ricart Maribel Diaz-Ricart Maribel Diaz-Ricart Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies development Frontiers in Immunology endothelial biomarkers early HCT complications laboratory diagnosis prognosis assessment response assessment |
| title | Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies development |
| title_full | Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies development |
| title_fullStr | Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies development |
| title_full_unstemmed | Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies development |
| title_short | Early vascular endothelial complications after hematopoietic cell transplantation: Role of the endotheliopathy in biomarkers and target therapies development |
| title_sort | early vascular endothelial complications after hematopoietic cell transplantation role of the endotheliopathy in biomarkers and target therapies development |
| topic | endothelial biomarkers early HCT complications laboratory diagnosis prognosis assessment response assessment |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1050994/full |
| work_keys_str_mv | AT anabelenmorenocastano earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT anabelenmorenocastano earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT anabelenmorenocastano earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT mariaqueraltsalas earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT martapalomo earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT martapalomo earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT martapalomo earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT juliamartinezsanchez earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT juliamartinezsanchez earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT montserratrovira earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT francescfernandezaviles earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT carmenmartinez earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT joancid earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT joancid earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT pedrocastro earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT pedrocastro earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT pedrocastro earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT ginesescolar earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT ginesescolar earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT ginesescolar earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT enriccarreras earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT enriccarreras earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT maribeldiazricart earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT maribeldiazricart earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment AT maribeldiazricart earlyvascularendothelialcomplicationsafterhematopoieticcelltransplantationroleoftheendotheliopathyinbiomarkersandtargettherapiesdevelopment |